News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Johnson & Johnson (JNJ) Prostate Cancer Drug So Effective Trial Stopped



6/4/2012 7:01:00 AM

A new study shows that Johnson & Johnson‘s prostate cancer pill Zytiga dramatically slows the progression of the disease in men who are not yet sick enough to start chemotherapy. Zytiga is already approved for use in patients after chemotherapy including the drug Taxotere has been given. J&J had announced that the study was positive in April after an independent committee said it was no longer ethical to give some patients placebo. J&J is releasing full results today at the annual meeting of the American Society of Clinical Oncology in Chicago. In the 1,088-patient clinical trial, patients who received a combination of Zytiga and the steroid prednisone were 57% less likely to see their cancer advance based on a measure called radiographic progression free survival (rPFS), a more exacting version of the progression free survival (time without the tumor growing) measure used in earlier prostate cancer studies.

Read at Forbes
Read at Fox News
Read at Seeking Alpha
Read at Chicago Tribune
Read at SF Gate


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES